Short Interest in CytoDyn Inc. (OTCMKTS:CYDY) Expands By 15.0%

CytoDyn Inc. (OTCMKTS:CYDY) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 20,123,400 shares, an increase of 15.0% from the December 15th total of 17,499,100 shares. Based on an average trading volume of 6,176,200 shares, the days-to-cover ratio is currently 3.3 days.

CytoDyn Stock Performance

Shares of CytoDyn stock traded up $0.00 during midday trading on Friday, reaching $0.15. 1,217,001 shares of the company’s stock traded hands, compared to its average volume of 2,325,929. CytoDyn has a 52 week low of $0.10 and a 52 week high of $0.32. The company’s 50 day simple moving average is $0.12 and its 200 day simple moving average is $0.14. The company has a market cap of $185.14 million, a price-to-earnings ratio of -7.54 and a beta of -0.10.

CytoDyn (OTCMKTS:CYDY) last posted its earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share for the quarter.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.